Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward H Romond

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Current Problems in Cancer|November 7, 2016
Systemic therapy for HER2-positive early-stage breast cancerAju Mathew, Edward H Romond
Clinical Advances in Hematology & Oncology : H&O|June 2, 2006
Advances in adjuvant therapy for breast cancerDennis J Slamon, Edward H Romond, Edith A Perez, et al.
Journal of the National Cancer Institute|November 1, 2015
Time-Varying Effects of Breast Cancer Adjuvant Systemic TherapyIsmail Jatoi, Hanna Bandos, Jong-Hyeon Jeong, et al.
Pathology Research International|December 15, 2010
Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas?Mathew Purdom, Michael L Cibull, Terry D Stratton, et al.
Cancer|April 17, 2023
Influence of depression on breast cancer treatment and survival: A Kentucky population-based studyFeitong Lei, Robin C Vanderpool, Laurie E McLouth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31Edith A Perez, Edward H Romond, Vera J Suman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2015
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38Reena S Cecchini, Sandra M Swain, Joseph P Costantino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Problems in Cancer|November 7, 2016
Systemic therapy for HER2-positive early-stage breast cancerAju Mathew, Edward H Romond
Clinical Advances in Hematology & Oncology : H&O|June 2, 2006
Advances in adjuvant therapy for breast cancerDennis J Slamon, Edward H Romond, Edith A Perez, et al.
Journal of the National Cancer Institute|November 1, 2015
Time-Varying Effects of Breast Cancer Adjuvant Systemic TherapyIsmail Jatoi, Hanna Bandos, Jong-Hyeon Jeong, et al.
Pathology Research International|December 15, 2010
Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas?Mathew Purdom, Michael L Cibull, Terry D Stratton, et al.
Cancer|April 17, 2023
Influence of depression on breast cancer treatment and survival: A Kentucky population-based studyFeitong Lei, Robin C Vanderpool, Laurie E McLouth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31Edith A Perez, Edward H Romond, Vera J Suman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2015
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38Reena S Cecchini, Sandra M Swain, Joseph P Costantino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Pageof 2